Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)


Background: The bone-targeting agents (BTAs) denosumab and bisphosphonates (BPs) are widely used in the supportive care of patients (pts) with CRPC and bone metastases. We present data on pts treated with radium-223 dichloride (Ra-223) with or without a concomitant BTA in an international EAP.

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223.

Identifying a reliable marker of efficacy for radium-223 dichloride (Ra-223) would aid in the clinical management of mCRPC patients (pts).

Role of FSH in the musculoskeletal side effects associated with androgen deprivation therapy (ADT) for prostate cancer

Introduction: In the treatment of advanced prostate cancer, gonadotropin releasing hormone/luteinizing hormone releasing hormone (GnRH/LHRH) receptor agonists and antagonists both reduce testosterone to castrate levels. 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe